OncoCyte (OCX) Competitors $2.84 +0.01 (+0.35%) Closing price 04/17/2025 03:56 PM EasternExtended Trading$2.84 0.00 (0.00%) As of 04/17/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OCX vs. PHAT, RGNX, BNTC, ALLO, ORKA, TKNO, TRDA, MREO, HRTX, and CYRXShould you be buying OncoCyte stock or one of its competitors? The main competitors of OncoCyte include Phathom Pharmaceuticals (PHAT), REGENXBIO (RGNX), Benitec Biopharma (BNTC), Allogene Therapeutics (ALLO), Oruka Therapeutics (ORKA), Alpha Teknova (TKNO), Entrada Therapeutics (TRDA), Mereo BioPharma Group (MREO), Heron Therapeutics (HRTX), and Cryoport (CYRX). These companies are all part of the "pharmaceutical products" industry. OncoCyte vs. Phathom Pharmaceuticals REGENXBIO Benitec Biopharma Allogene Therapeutics Oruka Therapeutics Alpha Teknova Entrada Therapeutics Mereo BioPharma Group Heron Therapeutics Cryoport Phathom Pharmaceuticals (NASDAQ:PHAT) and OncoCyte (NASDAQ:OCX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings, community ranking and profitability. Which has more risk & volatility, PHAT or OCX? Phathom Pharmaceuticals has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Comparatively, OncoCyte has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Does the MarketBeat Community believe in PHAT or OCX? Phathom Pharmaceuticals received 85 more outperform votes than OncoCyte when rated by MarketBeat users. Likewise, 72.39% of users gave Phathom Pharmaceuticals an outperform vote while only 10.53% of users gave OncoCyte an outperform vote. CompanyUnderperformOutperformPhathom PharmaceuticalsOutperform Votes9772.39% Underperform Votes3727.61% OncoCyteOutperform Votes1210.53%Underperform Votes10289.47% Which has better valuation & earnings, PHAT or OCX? OncoCyte has lower revenue, but higher earnings than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than OncoCyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPhathom Pharmaceuticals$55.25M5.08-$201.59M-$5.35-0.75OncoCyte$1.88M43.18-$27.78M-$4.40-0.65 Do institutionals & insiders have more ownership in PHAT or OCX? 99.0% of Phathom Pharmaceuticals shares are held by institutional investors. Comparatively, 55.3% of OncoCyte shares are held by institutional investors. 24.1% of Phathom Pharmaceuticals shares are held by insiders. Comparatively, 1.6% of OncoCyte shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media refer more to PHAT or OCX? In the previous week, Phathom Pharmaceuticals had 5 more articles in the media than OncoCyte. MarketBeat recorded 5 mentions for Phathom Pharmaceuticals and 0 mentions for OncoCyte. Phathom Pharmaceuticals' average media sentiment score of 0.68 beat OncoCyte's score of 0.30 indicating that Phathom Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Phathom Pharmaceuticals Positive OncoCyte Neutral Is PHAT or OCX more profitable? Phathom Pharmaceuticals has a net margin of -1,292.14% compared to OncoCyte's net margin of -6,122.29%. Phathom Pharmaceuticals' return on equity of 0.00% beat OncoCyte's return on equity.Company Net Margins Return on Equity Return on Assets Phathom Pharmaceuticals-1,292.14% N/A -79.57% OncoCyte -6,122.29%-269.32%-59.71% Do analysts recommend PHAT or OCX? Phathom Pharmaceuticals currently has a consensus price target of $21.83, indicating a potential upside of 441.77%. OncoCyte has a consensus price target of $4.42, indicating a potential upside of 55.52%. Given Phathom Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Phathom Pharmaceuticals is more favorable than OncoCyte.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Phathom Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00OncoCyte 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 SummaryPhathom Pharmaceuticals beats OncoCyte on 13 of the 19 factors compared between the two stocks. Get OncoCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCX vs. The Competition Export to ExcelMetricOncoCyteDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$81.22M$2.30B$5.30B$7.35BDividend YieldN/A0.79%5.12%4.30%P/E Ratio-0.656.9321.8017.80Price / Sales43.1846.40379.9697.74Price / CashN/A15.7538.2634.64Price / Book1.152.936.443.98Net Income-$27.78M-$65.73M$3.21B$247.73M7 Day Performance2.16%-3.72%2.88%1.81%1 Month Performance-21.55%-18.95%-8.63%-6.98%1 Year Performance10.94%-17.83%11.46%1.29% OncoCyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCXOncoCyte2.2793 of 5 stars$2.84+0.4%$4.42+55.5%+9.7%$81.22M$1.88M-0.65120PHATPhathom Pharmaceuticals3.7283 of 5 stars$4.63-5.1%$22.17+378.8%-58.9%$322.42M$55.25M-0.81110Analyst ForecastNews CoverageRGNXREGENXBIO4.692 of 5 stars$6.33+7.5%$31.88+403.6%-65.1%$317.24M$83.33M-1.26370Analyst ForecastAnalyst RevisionNews CoveragePositive NewsBNTCBenitec Biopharma2.2266 of 5 stars$13.27+5.1%$24.71+86.2%+186.5%$311.20M$80,000.00-8.7920Short Interest ↑ALLOAllogene Therapeutics3.0069 of 5 stars$1.43-1.4%$9.29+549.6%-58.7%$310.69M$22,000.00-0.92310News CoverageORKAOruka Therapeutics3.0873 of 5 stars$8.14+6.0%$39.86+389.6%N/A$304.77MN/A-1.30N/AUpcoming EarningsNews CoverageTKNOAlpha Teknova1.1833 of 5 stars$5.67+1.4%$8.50+49.9%+173.0%$302.99M$37.75M-7.66240Positive NewsGap UpTRDAEntrada Therapeutics2.9953 of 5 stars$7.92+0.3%$25.67+224.1%-33.5%$297.75M$210.78M4.98110Positive NewsMREOMereo BioPharma Group2.0593 of 5 stars$1.90-2.6%$7.71+306.0%-10.9%$294.78M$1M-31.6740HRTXHeron Therapeutics3.4876 of 5 stars$1.93+1.0%$5.67+193.6%-33.6%$294.00M$144.29M-10.72300CYRXCryoport2.5262 of 5 stars$5.66-1.9%$11.83+109.1%-66.9%$282.49M$228.39M-1.671,020Analyst ForecastAnalyst Revision Related Companies and Tools Related Companies Phathom Pharmaceuticals Alternatives REGENXBIO Alternatives Benitec Biopharma Alternatives Allogene Therapeutics Alternatives Oruka Therapeutics Alternatives Alpha Teknova Alternatives Entrada Therapeutics Alternatives Mereo BioPharma Group Alternatives Heron Therapeutics Alternatives Cryoport Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OCX) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | Sponsored100-year-old investment secret predicts what?!A 100-year-old indicator has quietly predicted nearly every major market meltdown — including the Dot-Com Bust...Weiss Ratings | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OncoCyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share OncoCyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OCX Stock Free OCX Stock Alerts